Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Index movements reflect changes in component stock prices, earnings, macro data, and capital flows. This overview highlights the main drivers behind daily swings.
18,176 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
A legendary investor makes a bold AI move. He recently closed a position in a company famous for aggressive AI spend ...
If you want steady income and long-term growth, these five dividend stocks right now combine durable dividends with s...
After Microsoft's pullback, savvy investors look for durable megacap ideas. This guide highlights three top megacap s...
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
Piper Sandler moved to downgrade its Fastly target after Q1 FY2026 showed slowing core delivery volumes. The stock dr...
Arm Holdings’ stock has jumped sharply this year on AI data center demand, yet a valuation gap and monetization hurdl...
This deep-dive breaks down veru (veru) 2026 earnings, translating the quarterly numbers into a clear sense of cash he...
Fluence Energy surged nearly 100% in a week on big contract wins and a growing backlog. A quartet of AI-exposed energ...
As Palantir rolls out its Agentic AI Platform, analysts clash over value. This article breaks down the upside, the ri...
Bank of America delivers a solid first quarter, with earnings and trading activity rising, yet the stock trades lower...
Oracle's backlog surge and accelerating AI infrastructure growth are fueling a heated debate on whether the stock is ...